Mydecine Innovations Group Inc.
MYCO
CNSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -129.12% | -32.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -145.73% | -32.04% | |||
| Operating Income | 145.73% | 32.04% | |||
| Income Before Tax | 670.21% | 95.49% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 670.21% | 95.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 670.21% | 95.49% | |||
| EBIT | 145.73% | 32.04% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 671.05% | 95.49% | |||
| Normalized Basic EPS | 155.53% | 72.03% | |||
| EPS Diluted | 671.05% | 95.49% | |||
| Normalized Diluted EPS | 155.53% | 72.03% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||